Castrén & Snellman advised Rappta Therapeutics on the deal. Rappta Therapeutics, a Helsinki, Finland-based company focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A),…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
